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178 Does nasal and bronchial nitric oxide in CF correlate to pathogen
colonization in both airway levels?
R. Michl1, J. Hentschel1, C. Fischer1, J.F. Beck2, J.G. Mainz1. 1Children’s
Hospital of the University Jena, Pulmonology and CF Center, Jena, Germany;
2Children’s Hospital of the University Jena, Jena, Germany
Objectives: Nitric oxide (NO) is produced within the respiratory tract and can
be detected in exhaled bronchial and nasal air with correlation to speciﬁc diseases
(elevated in asthma/bronchiectasis, decreased in ciliar dysfunction). NO in paranasal
sinuses is considered as location-speciﬁc ﬁrst line defense mechanism. In CF, NO
levels are reported divergently as low or normal. Aim of this study was to investigate
correlation of upper and lower airway NO levels to pathogen colonization, clinics
and blood inﬂammatory parameters.
Methods: From 57 CF patients nasal and bronchial NO was correlated to pathogen
colonization of the upper and lower airways and clinical parameters. Airway
microbiology was preferably assessed by nasal lavage using 10ml NaCl 0.9% per
nasal side and sputum sampling.
Results: Nasal and bronchial NO levels were signiﬁcantly correlated to each
other, but not to speciﬁc pathogen colonization. In patients receiving azithromycin,
a tendency to reduced NO could be found. Interestingly, a signiﬁcant inverse
correlation between C-reactive protein and leucocytes and nasal NO was found.
In contrast, bronchial NO levels showed no correlation to clinical parameters, lung
function, body mass index, or inﬂammatory parameters.
Conclusion: Assessment of nasal and bronchial NO levels can contribute to
understand pathogen defense mechanisms in both airway levels in CF and other
diseases, and for its non-invasiveness, it allows repeated controls. Supposing NO
(in particular in the paranasal sinus) is part of ﬁrst line defense mechanism against
pathogens, further research may help preventing early colonization and improve
therapy options and outcome in CF.
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CF patients usually have an intermittent period of PA infection before they become
chronically infected. To date, there is no clearly identiﬁed which is the best practice
for early treatment of PA infection.
Objective: To compare two different eradication treatments against initial PA
infection.
Methods: Observational, analytic and retrospective cohort study. Clinical reports
from patients assisted at our Center were reviewed and those with ﬁrst acquisition
of PA between 1997 and 2011 were included. Age at ﬁrst acquisition, gender,
and genetics were considered. Two types of treatment were indicated: Group1:
Oral ciproﬂoxacin plus inhaled colistin for three months or Group 2: Intravenous
Ceftazidime plus amikacin during 14 days. Time to recurrence of PA, eradication
treatment rate (six months free of PA or more) and effective treatment (at least one
culture negative after treatment) were the analyzed variables. Kaplan Meier curves
were performed.
Results: 26 patients (15 males) in group 1and 39 patients (24 males) in group 2
were included. The median age (interquartile range) at ﬁrst acquisition was 1.8 years
(0.6 to 4.2) and 0.8 years (0.3 to 1.7) for group 1 and 2, respectively (NS). 67%
and 62% of the patients had p.F508 del mutation in each group (NS). The median
time to recurrence was 13 months (3.2 to 24) in group 1 and 5 months (0 to 11)
in group 2 (p< 0.01). Effective treatment and eradication treatment were 81% vs.
69% (NS) and 69% vs. 48% (NS) for group 1 and 2, respectively.
Conclusion: In our study, oral ciproﬂoxacin plus inhaled colistin was a better
option than intravenous Ceftazidime plus amikacin for the treatment of the early
PA infection.
180 Pseudomonas aeruginosa colonization of the respiratory tract in
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Introduction: Patients with cystic ﬁbrosis (CF) are susceptible to lower respiratory
tract infections with Pseudomonas aeruginosa (PA). Once infection is established
progressive lung disease often worsens morbidity and mortality risks.
Objectives: To characterize PA colonization in our population and evaluate how
lung function and nutritional status change over time.
Methods: Retrospective clinical review of CF patients followed in the paediatric
units of 2 level III hospitals in the north of Portugal. Evaluated variables: age of
diagnosis, genotype, body mass index (BMI) and FEV1. PA colonization categories:
never grown, free (last year); intermittent (<2 positive cultures last year); chronic
(2 positive cultures last year). Deceased patients were excluded.
Results: Seventy-one patients were included. The prevalence of PA positive res-
piratory cultures was 59.2%; 60.5% were females (p> 0.05). PA colonization was
chronic in 26.2%, intermittent in 31.0% and free in 42.9%. Colonization was higher
(74.1% vs. 50.0%) when the diagnosis of CF was made in the ﬁrst 6 months of life
(p = 0.045) with a median age at diagnosis of 0.75 (0.08–15.01) vs. 2.58 (0–14.0)
years (p = 0.020). Delta F508 homozygotes were more frequently colonized than
other genotypes (73.0% vs. 44.1%; p = 0.013). Culture-positive patients also had a
lower FEV1 (69.7±25.2 vs. 72.2±28.3%; p> 0.05) and a lower BMI at diagnosis
(15.02±3.08 vs. 15.92±2.07 kg/m2; p> 0.05).
Conclusion: The prevalence of PA colonization in our sample was signiﬁcantly
related with an early age at diagnosis and delta F508 genotype, and it seemed to
correlate with poorer nutritional status and lung function decline.
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Introduction: Pseudomonas aeruginosa (PA) establishes chronic infection in pa-
tients with CF and is associated with pulmonary exacerbations (PE). A previous
audit found no association between in vitro antibiotic susceptibility and clinical
outcome. As a result we rationalised susceptibility testing for children with chronic
PA infection.
Methods: A 25-month retrospective case-note audit of 55 patients attending the
Nottingham Paediatric CF unit, who have had PA isolated, examined data from the
period pre- and post-protocol change. Courses of IV antibiotics, clinical outcomes,
microbiology results and factors affecting recovery from PE were identiﬁed;
regression and economic analyses were undertaken.
Results: No difference in clinical outcomes for patients with PA infection was
identiﬁed following the rationalisation of testing. The new protocol was followed
on 64% of occasions, resulting in possible savings of 58.1% (£207) in 9 months.
Factors identiﬁed as affecting the success of treatment were BMI before treatment;
age on admission; genotype; chronic oral antibiotics; courses of IV antibiotics
completed at home; and semi-elective, compared to symptomatic, admissions. When
multiple samples were taken on the same day, 70.8% (n = 17) were found to be non-
concordant. The negative predictive value of cough swabs was 30.8%.
Conclusions: This is the ﬁrst analysis of the rationalised protocol at the unit. The
rationalised protocol appears to have had no effect upon clinical outcome but has
reduced the cost of testing. Previous ﬁndings of poor predictability of cough swab
samples are replicated and some factors predictive of treatment failure are identiﬁed.
